Roche reports positive Phase II results with potential first-in-class treatment for the negative symptoms of schizophrenia
There are currently no effective therapies available for the treatment of negative symptoms, a core clinical feature of schizophrenia. These symptoms include apathy, lack of pleasure, lack of emotion and poor social functioning. Clinically disabling in more than 50% of all patients with schizophrenia, negative symptoms represent an important unmet medical need, and are associated with a substantial socio-economic burden.
"We are greatly encouraged by these clinical data with the novel glycine transporter-1 inhibitor RG1678" said Eugene Tierney, Head of the Central Nervous System Disease Biology Area at Roche. "Today’s therapeutic options fail to address these symptoms and also have many adverse side-effects. New treatment options harnessing novel modes of action such as RG1678 could offer relief to patients with this devastating disease and ease economic burden to society".
The analysis of this double blind phase II study showed that RG1678 has a robust and clinically meaningful effect in patients with schizophrenia. Improvements were observed on negative symptoms, overall physician’s assessment (clinical global impression) and patient’s personal and social performance in a prospectively defined intent to treat population. RG1678 was given as an add-on treatment to patients who were stable on antipsychotic therapy and suffered mainly from negative or disorganized thought symptoms. The compound was well tolerated at all doses tested.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.